A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

Recruiting

Phase 1

TSC-100 & TSC-101A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

Sponsor:

TScan Therapeutics, Inc.

Code:

NCT05473910

Conditions

AML

MDS

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SOC + TSC-101

Control

SOC + TSC-100

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-14. This information was provided to ClinicalTrials.gov by TScan Therapeutics, Inc. on 2026-07-13.